Firms fined £260mln over 10,000% rise in price of NHS drugs
"These are without doubt some of the most serious abuses we have uncovered in recent years"
Company
Allergan
NYSE:AGN
Allergan is a global specialty pharmaceutical company, which develops and commercialises products for eye care, neuromodulator, skin care and other specialty markets. Its products are sold in over 100 countries worldwide and include the successful and popular Botox and Botox cosmetics treatments.
90 stories · page 1 of 5
LATE MOVERS: Costco climbs after bulk retailer’s Q2 earnings blow past Wall Street estimates
Also making moves were H&R Block, Burlington and GM
Genprex adds pharma veteran John Bonfiglio to board
Most recently, Bonfiglio served as CEO of Oragenics and then played a key role in TapImmune’s merger with Marker Therapeutics
Aptinyx stock falls after NYX-2925 trial for treating painful diabetic nerve damage fails to meet endpoint
However, the biotech said it will still conduct an exploratory Phase 2 study of NYX-2925 for treating patients with fibromyalgia or muscle pain
Allergan shrinks net loss in 3Q thanks to Botox sales and lifts earnings forecast
Botox was a big seller in the quarter, as its sales rose 13.6% to $879.7 million
IPO Roundup: Biotechs dominate this week's slate of 12 IPOs
A property management company and a fintech round out a heavy slate of new issues this week
Investors like the idea of Allergan selling two small units, having a laser focus on core areas
CEO Brent Saunders said the drug giant will use proceeds to buy back shares, cautioning ‘there is no fire sale’
Axovant shares jump after welcoming former Allergan and Teva execs to its management team
The biotech's CEO, COO and three board members departed the company in February
Allergan 1Q tops analyst estimates as pharma giant raises full-year guidance
Sales of Botox and Juvederm Collection rise by double-digit percentages though Restasis sales slide
Shire: Takeda deadline looms, but will other bidders emerge for in-play £43bn drugs group?
Next week we'll see the colour of Takeda's money. Will rival bidders emerge from the woodwork?
Archive
Lloyds, Barclays, RBS, GSK and Shire kick off earnings season for banks and pharmas
The week ahead in includes updates from Lloyds, Barclays, RBS, Shire, GSK, Whitbread, Persimmon and Shell
FTSE 100 puts in late spurt to close comfortably higher
Shire shares propped up the rest of the Footsie leader-board despite Takeda unveiling an improved offer for the drugs maker
ReNeuron appoints new chief medical officer based in recently established US office
The AIM-listed firm said Dr Richard Beckham will replace Dr Julian Howell, who has left the company to pursue another opportunity
Apricus goes flat as FDA refuses to approve erectile dysfunction treatment
It’s the second time regulators have given the thumbs-down to Vitaros, with the FDA flagging concerns over one of the ingredients in the cream as well as with the manufacturing process
Allergan Q4 earnings top Wall Street forecasts; migraine drug succeeds in late-stage trial
It was a double dose of good news for Allergan investors: Q4 results came in better than expected, while ubrogepant succeeded in a key trial
Allergan, Seagate Technology, Urban Outfitters - AFTER HOURS
Proactive stayed up to have a look at what was piquing interest after the bell in New York
Conagra Brands, Allergan, Accenture, Nike and more - PRE-MARKET
Proactive takes a look at the stocks piquing interest before the bell in New York
Allergan lands FDA approval for schizophrenia drug
"We are pleased that the FDA has recognized the benefits of VRAYLAR for maintenance treatment of adults with schizophrenia."
Teva Pharmaceutical tanks in Tel Aviv after third quarter earnings
Yesterday, Allergan said it would start to sell off its nearly 10% stake in Teva
Botox maker Allergan pumps up despite third quarter loss
The firm unveiled a net loss of US$4.03bn compared with a profit of US$15.15bn a year earlier